Tags

Type your tag names separated by a space and hit enter

The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.
Epilepsy Behav. 2017 05; 70(Pt B):288-291.EB

Abstract

In the United States, federal and state laws regarding the medical use of cannabis and cannabinoids are in conflict and have led to confusion among patients, caregivers, and healthcare providers. Currently, cannabis is legal for medical purposes in 50% of the states, and another seventeen states allow products that are high in cannabidiol (CBD) and low in THC (tetrahydrocannabinol) for medical use. Many of these artisanal products are sold in dispensaries or over the internet. However, none of these products has been approved by the Food and Drug Administration (FDA). Understanding how federal laws apply to clinical research and practice can be challenging, and the complexity of these laws has resulted in particular confusion regarding the legal status of CBD. This paper provides an up-to-date overview (as of August 2016) of the legal aspects of cannabis and cannabidiol, including cultivation, manufacture, distribution, and use for medical purposes. This article is part of a Special Issue title, Cannabinoids and Epilepsy.

Authors+Show Affiliations

GW Pharmaceuticals, Inc., 5800 Armada Dr., Suite 210, Carlsbad, CA 92008, United States. Electronic address: apm@gwpharm.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28169144

Citation

Mead, Alice. "The Legal Status of Cannabis (marijuana) and Cannabidiol (CBD) Under U.S. Law." Epilepsy & Behavior : E&B, vol. 70, no. Pt B, 2017, pp. 288-291.
Mead A. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav. 2017;70(Pt B):288-291.
Mead, A. (2017). The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy & Behavior : E&B, 70(Pt B), 288-291. https://doi.org/10.1016/j.yebeh.2016.11.021
Mead A. The Legal Status of Cannabis (marijuana) and Cannabidiol (CBD) Under U.S. Law. Epilepsy Behav. 2017;70(Pt B):288-291. PubMed PMID: 28169144.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. A1 - Mead,Alice, Y1 - 2017/02/04/ PY - 2016/10/20/received PY - 2016/11/13/revised PY - 2016/11/14/accepted PY - 2017/2/9/pubmed PY - 2018/1/18/medline PY - 2017/2/8/entrez KW - Cannabidiol KW - Cannabinoids KW - Cultivation KW - Hemp KW - Medical use KW - Transportation SP - 288 EP - 291 JF - Epilepsy & behavior : E&B JO - Epilepsy Behav VL - 70 IS - Pt B N2 - In the United States, federal and state laws regarding the medical use of cannabis and cannabinoids are in conflict and have led to confusion among patients, caregivers, and healthcare providers. Currently, cannabis is legal for medical purposes in 50% of the states, and another seventeen states allow products that are high in cannabidiol (CBD) and low in THC (tetrahydrocannabinol) for medical use. Many of these artisanal products are sold in dispensaries or over the internet. However, none of these products has been approved by the Food and Drug Administration (FDA). Understanding how federal laws apply to clinical research and practice can be challenging, and the complexity of these laws has resulted in particular confusion regarding the legal status of CBD. This paper provides an up-to-date overview (as of August 2016) of the legal aspects of cannabis and cannabidiol, including cultivation, manufacture, distribution, and use for medical purposes. This article is part of a Special Issue title, Cannabinoids and Epilepsy. SN - 1525-5069 UR - https://www.unboundmedicine.com/medline/citation/28169144/The_legal_status_of_cannabis__marijuana__and_cannabidiol__CBD__under_U_S__law_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1525-5050(16)30585-6 DB - PRIME DP - Unbound Medicine ER -